

Glucodent Ltd. has, through the company Maiwald GmbH, submitted its second patent application to the European Patent Office in order to protect its intellectual property.

With this patent, Glucodent Ltd. secures intellectual property protection for the formulation of a future medical product.

The patent has been filed with the European Patent Office via Maiwald GmbH.

This invention relates to a medical formulation intended for alleviating and eliminating periodontal issues, which are particularly pronounced in individuals with diabetes.

Filing this patent represents an important legal step that ensures the protection of developed solutions and enables further development of the future medical product.

By submitting this second patent application, the prerequisites for the next phase of product development—clinical trials—have been established.

Glucodent Ltd. represents an advanced research and development project focused on creating a specialized product for oral pathology intended for people with diabetes. Our mission is to improve oral health and the wellbeing of people with diabetes through an innovative and scientifically proven product.

The project relies on the expertise of leading scientific institutions and our distinguished team of scientists. Additionally, we collaborate with experts in key areas such as intellectual property (IP), legal affairs, regulatory compliance, and strategic consulting. This comprehensive approach enables us to meet the highest quality standards alongside product efficacy.